In most studies, p53 nuclear accumulation is predictive of tumor recurrence, progression and mortality.[45–52] However, a meta-analysis by Malats reviewing 117 studies spanning 10 years of research concluded that the evidence is not yet sufficient to conclude whether changes in P53 act as markers of outcome in patients with bladder cancer.[53] A second review by Schmitz-Drager analyzing 43 trials determined that in only one-half did p53 retain prognostic significance upon multivariate analysis. Here, TP53 is linked to urinary bladder carcinoma.